NextCure, Inc. - 8-K Filing
NextCure presented Phase 1 dose escalation data showing an objective response rate (ORR) of 55% in gynecologic cancers and 52.9% in ovarian cancer at therapeutic doses (4.8–8.0 mg/kg). The trial included 59 patients across the U.S. and China, with safety data indicating manageable adverse events predominantly hematological or gastrointestinal.
Tickers: $NXTC